Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVP 21D9

Drug Profile

AVP 21D9

Alternative Names: AVP 22G12; AVP 8C1; AVP-21D9; AVP-3E7/G3; AVP-V-7-27; Thravixa

Latest Information Update: 17 Mar 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avanir Pharmaceuticals
  • Developer Avanir Pharmaceuticals; Emergent BioSolutions
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Anthrax toxin inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anthrax
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Anthrax
  • Discontinued Staphylococcal infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Anthrax in USA (IV, Infusion)
  • 08 Mar 2013 AVP 21D9 receives Orphan Drug status for Anthrax in European Union
  • 21 Feb 2012 Emergent BioSolutions completes its phase I trial in Healthy volunteers in USA (NCT01202695)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top